Sponsor study identifier
interventional
20
1 country
2
Study Start
November 1, 2021
Actual (reported)Primary Completion
December 1, 2024
Actual (reported)Study Completion
December 1, 2024
Actual (reported)Adolescents with Type 1 Diabetes (age 13-18 years, T1D duration \>6 months managed on insulin) and poor glycemic control will wear a blinded CGM to obtain baseline data. After assuring adherence to CGM wear, participants will receive a non-blinded CGM and will share their blood glucose levels with the study team. Clinical personnel will remotely monitor patients in real-time for 3 months and communicate regularly over secure text messaging with participants and their parents. Following active remote monitoring, the participants will wear a non-blinded CGM for 3 months. Primary outcome assessment will be the change in HbA1c after 3 months of real-time remote continuous glucose monitoring.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1, 2024
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 17, 2020
Actual (reported)September 7, 2020
Actual (reported)November 1, 2021
Actual (reported)December 1, 2024
Actual (reported)December 1, 2024
Actual (reported)March 3, 2026
Actual (reported)Change in Hemoglobin A1c From Baseline to 3 Months
Change in hemoglobin A1c from baseline to 3 months (three-month follow-up visit after remote continuous glucose monitoring and secure text messaging)
3 months
Change in Depression Score After Clinical Remote CGM Monitoring and Secure Text Messaging.
3 months
Change in Quality of Life Score After Clinical Remote CGM Monitoring and Secure Text Messaging.
3 months
Change in Self Efficacy Score After Clinical Remote CGM Monitoring and Secure Text Messaging.
3 months
Change in Parent-child Collaboration Score After Clinical Remote CGM Monitoring and Secure Text Messaging.
3 months
Participants will be provided with a Dexcom G6 continuous glucose monitor for the duration of the study.
A secure platform (TigerConnect) will be used for three-way communication between parents, participants, and clinical personnel
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Childrens Medical Center
Dallas, Texas, 75390, United States
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
This was a pilot study so overall number of participant enrolled and ultimately assigned to the study arm was small.
20 participants (actual enrollment reported by the registry).
First Submitted
July 17, 2020
First Posted
September 7, 2020
Study Start
November 1, 2021
Actual (reported)Contact the study team to confirm eligibility.
Primary Completion
December 1, 2024
Actual (reported)Study Completion
December 1, 2024
Actual (reported)Last Updated
March 3, 2026
Results First Posted
March 3, 2026
Record last verified: 2026-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: